Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the following criteria:~  * plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score ≥12 in affected skin at screening and baseline~ * sPGA score of ≥3 at screening and baseline~* Candidate for biologic treatment for psoriasis.~Exclusion Criteria:~* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data.~* Breastfeeding or nursing (lactating) women.~* Have had serious, opportunistic, or chronic/recurring infection within 6 months prior to screening.~* Have received live vaccine(s) (included attenuated live vaccines) within 1 month of screening or intend to during the study.~* Have any other skin conditions (excluding psoriasis) that would affect interpretation of the results.~* Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days prior to baseline.~* Have received topical psoriasis treatment within 14 days prior to baseline.~* Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17 targeting biologics within 8 weeks prior to baseline.~* Have previous exposure to any biologic therapy targeting IL-23 (including ustekinumab), either licensed or investigational (previous briakinumab use is permitted).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 30 mg Mirikizumab (Type: EXPERIMENTAL): 30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
- 100 mg Mirikizumab (Type: EXPERIMENTAL): 100 mg Mirikizumab administered SC Q8W.
- 300 mg Mirikizumab (Type: EXPERIMENTAL): 300 mg Mirikizumab administered SC Q8W.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC Q8W.

Based on this trial design, predict the completion outcome and termination type (if applicable).